UNSPSC 51362603: Acebrochol

This classification denotes a sedative and hypnotic with the molecular formula C29H48Br2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7XZB016MY5, chemically known as 5,6beta-dibromo-5alpha-cholestan-3beta-ol acetate but generally known as acebrochol, which bears US NIH Compound Identifier 170366. European Medicines Agency schedules Acebrochol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07369MIG. The term ACEBROCHOL is an International Non-Proprietary Name.

UNSPSC 51362603 Acebrochol (Commodity) covers pharmaceutical products and active pharmaceutical ingredients procured by state and local health agencies, though recent solicitations tagged under this code reflect a broader pharmaceutical procurement landscape that includes naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products. State and local issuing bodies under this code span county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. Solicitations require vendors to meet FDA compliance, Good Manufacturing Practice certification, Drug Supply Chain Security Act adherence, and specific insurance thresholds; delivery, packaging specifications, and electronic data interchange capability are standard requirements. Pricing models vary from fixed-fee arrangements to net pricing and WAC-minus structures, with contracts typically running two years with renewal options.

Recent activity shows geographic concentration in Florida and Minnesota, with cross-state reach through cooperative purchasing vehicles. Seminole County, Florida issued IFB 60459723LAS (posted Jun 30, 2026, due Jul 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted Apr 3, 2026) to gather vendor capabilities for a direct-to-manufacturer prescriptions program, signaling preliminary market research before a formal RFP. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released RFP S1070000015802 (posted Jan 20, 2026, due Mar 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with pricing weighted 75 percent on competitiveness and awards effective July 1, 2026. The code shows active procurement across health departments and cooperative purchasing intermediaries but reflects practical pharmaceutical supply activity that extends beyond the acebrochol commodity name alone.